Who
Veronique Lecault
Chief Technology Officer
Company insider
Files Form 4 as: Chief Technology Officer, AbCellera Biologics.
In numbers
- Trades disclosed
- 28
- Buys
- 4
- Sells
- 1
- Bought
- $3.8M
- Sold
- $25.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Oct 2020
- Last trade
- 1 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jan 2026filed 5 Jan 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —539,265 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —539,265 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —832,033 at $0.00 | filing |
| 21 Jun 2024filed 24 Jun 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —83,334 at $0.00 | filing |
| 21 Jun 2024filed 24 Jun 2024 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $16K83,334 at $0.19 | filing |
| 14 Jan 2024filed 16 Jan 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —770,416 at $0.00 | filing |
| 12 Sep 2023filed 14 Sep 2023 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $104K20,000 at $5.19 | filing |
| 5 May 2023filed 9 May 2023 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —250,000 at $0.00 | filing |
| 5 May 2023filed 9 May 2023 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $48K250,000 at $0.19 | filing |
| 1 Dec 2022filed 5 Dec 2022 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —462,535 at $0.00 | filing |
| 16 May 2022filed 17 May 2022 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $1.3M200,000 at $6.34 | filing |
| 28 Feb 2022filed 1 Mar 2022 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Bought | $2.0M230,789 at $8.66 | filing |
| 8 Dec 2021filed 3 Feb 2022 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code G | —250,000 at $0.00 | filing |
| 8 Dec 2021filed 9 Dec 2021 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —250,000 at $0.00 | filing |
| 8 Dec 2021filed 9 Dec 2021 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $48K250,000 at $0.19 | filing |
| 7 Dec 2021filed 9 Dec 2021 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —406,020 at $0.00 | filing |
| 30 Nov 2021filed 3 Feb 2022 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code G | —83,333 at $0.00 | filing |
| 30 Nov 2021filed 3 Dec 2021 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —83,333 at $0.00 | filing |
| 30 Nov 2021filed 3 Dec 2021 | ABCL AbCellera BiologicsBiotechnology | SEC FORM 4 Code M | $16K83,333 at $0.19 | filing |
| 30 Nov 2021filed 2 Dec 2021 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —83,333 at $0.00 | filing |
News
AbCellera Biologics (NASDAQ:ABCL) Research Coverage Started at UBS GroupABCL · themarketsdaily.com · 15 Oct 2026Head to Head Review: Surrozen (NASDAQ:SRZN) vs. AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 14 Oct 2026Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)ABCL · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Veronique Lecault; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.